WO2014054841A1 - Composition comprenant une matière pour la régulation de l'expression de l'antigène abh - Google Patents

Composition comprenant une matière pour la régulation de l'expression de l'antigène abh Download PDF

Info

Publication number
WO2014054841A1
WO2014054841A1 PCT/KR2013/001756 KR2013001756W WO2014054841A1 WO 2014054841 A1 WO2014054841 A1 WO 2014054841A1 KR 2013001756 W KR2013001756 W KR 2013001756W WO 2014054841 A1 WO2014054841 A1 WO 2014054841A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
expression
acid
abh antigen
substance
Prior art date
Application number
PCT/KR2013/001756
Other languages
English (en)
Korean (ko)
Inventor
홍용덕
신송석
한상훈
김겸손
정진호
오장희
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Publication of WO2014054841A1 publication Critical patent/WO2014054841A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • a composition comprising a substance that modulates the expression of an ABH antigen
  • the present invention relates to an anti-aging or moisturizing composition.
  • Blood type antigens refer to specific antigenic striking structures found in glycoproteins or glycolipids on the surface of blood red blood cells. Representative examples include AB0 blood type antigens (ABH antigens) and Lewis type blood type antigens. Blood types are determined according to the glycosylation terminal group structure of a specific structure. AB0 blood type antigens and Lewis blood type antigens are not only expressed in red blood cells, but are found in various parts of the human body. In particular, AB0 blood type antigens are expressed in the epithelium of the esophagus, stomach, and small intestine, depending on the individual's blood type. It is known and is expressed in the granular layer of the epidermis in the skin.
  • the expression of the granular layer of the epidermis of the AB0 blood group antigen is shown in the outermost layer of the skin anatomically and is closely related to skin-related diseases, particularly inflammatory diseases.
  • AB0 blood group antigens are very important antigens for the rejection of blood transfusions and organ transplants, but since their discovery in 1900, little has been studied on physiological functions other than rejection.
  • the inventors of the present invention have confirmed that the substance regulating the expression of the ABH antigen not only has an anti-aging effect, but also has a skin moisturizing effect, thereby completing the present invention.
  • An object of the present invention is to provide a composition that brings anti-aging or moisturizing efficacy.
  • the present invention provides a composition for anti-aging comprising a substance for regulating the expression of the ABH antigen as an active ingredient.
  • the present invention also provides a moisturizing composition comprising a substance for regulating the expression of the ABH antigen as an active ingredient.
  • composition according to the present invention contains a substance for regulating the expression of the ABH antigen as an active ingredient, has an excellent anti-aging and moisturizing effect.
  • the composition of the present invention is also MMP-1 It can be usefully used to alleviate or improve wrinkles by inhibiting expression.
  • Figure 1 shows the structure of the ABH antigen and Lewis blood type antigen.
  • Figure 2 is a result of confirming that the expression of B antigens in HaCaT cell line is increased by a substance that controls the expression of ABH antigens.
  • MMP-1 collagenase
  • Figure 4 shows the effect of inhibiting the expression of MMP-1 (collagenase) in HaCaT cells.
  • the present invention relates to an anti-aging composition
  • an anti-aging composition comprising, as an active ingredient, a substance that controls the expression of an ABH antigen.
  • ABS antigen 'glycoprotein black on the surface of red blood cells of the blood refers to a specific antigenic structure expressed in glycolipids, typically ABH antigen is represented ABB antigen represented in Figure 1, Lewis It is used to include all aggregates of ABH antigen analogues, such as blood-type antigens, etc.
  • ABH antigen analogues are substances to which monosaccharides, amino acids, etc. are additionally bound, and mean substances having the same functions as the original functions of ABH antigens.
  • Figure 1 shows the structure of the ABH antigen and Lewis type blood type antigen.
  • anti-aging 'means to slow the change of the body that changes over time, and specifically, examples of improving wrinkles, reducing wrinkles or reducing color deposition such as blotch
  • aging may be delayed by inhibiting the expression of MMP.
  • active ingredient means a component that can exhibit activity alone or in combination with a carrier having no desired activity.
  • the agent for controlling the expression of the ABH antigen includes a substance for increasing the expression of the ABH antigen. Increasing the expression of such ABH antigen may be specifically expressed through increased expression of B antigen in HaCaT cell line.
  • the agent for controlling the expression of the ABH antigen is 1,3-dicaffeoylquinic acid (1,3-dicaffeoylquinic acid), 1,5-dicapeo At least one compound selected from the group consisting of 1,5-dicafeoylquinic acid and amentoflavon, derivatives thereof or pharmaceutically acceptable Salts thereof.
  • derivative means any compound that is changed into another substituent at a substitutable position of the compound, and there is no limitation in the kind of such substituents.
  • pharmaceutically acceptable means a conventional medical dosage (medicinal can be approved or approved by the government or equivalent regulatory body for use in animals, more specifically in humans, by avoiding significant toxic effects when used in dosage form, or as listed in a pharmacopeia or other general pharmacopeia. It means to be.
  • the salt is formed by (1) an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfuric acid nitrate, or the like; Or acetic acid, propionic acid, nucleoanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4- Hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane- disulfonic acid, 2-hydroxyethanesulfonic acid, benzenebenzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2 Naphthalenesulfonic acid, 4-tolu
  • the composition may include a substance for controlling the expression of the ABH antigen in an amount of 0.001% to 20% by weight based on the total weight of the composition.
  • the substance that controls the expression of the ABH antigen is used in the above range, it is not only suitable for showing the anti-aging effect of the anti-aging and anti-wrinkle, as intended by the present invention, and also satisfies both the stability and safety of the composition. This is useful in terms of cost effectiveness.
  • the composition of the present invention is 0.005% by weight to 19.5% by weight, 0.01% by weight to 19% by weight, 0.015% by weight to 18.5% by weight, 0.02% by weight relative to the total weight of the substance composition for controlling the expression of the ABH antigen % To 18% by weight, 0.025% to 17.5% by weight, 0.03% to 17% by weight, 0.035% to 16.5% by weight, 0.04% to 16% by weight, or 0.045% to 15.5% by weight. have.
  • the composition is MMP1
  • the composition of the present invention can inhibit the expression of matrix metal loproteinases.
  • the composition of the present invention may inhibit or inhibit the expression of the MMP1 gene, or may inhibit the activity of the MMP1 protein by inhibiting its activity.
  • the present invention relates to a moisturizing composition comprising, as another active ingredient, a substance that controls the expression of the ABH antigen.
  • composition of the present invention can increase the skin moisturizing power by increasing the expression of the ABH antigen.
  • the material for controlling the expression of the ABH antigen may be a substance that increases the expression of the ABH antigen.
  • the material for controlling the expression of the ABH antigen is 1,3-dicaffeoylquinic acid (1,3-dicaffeoylquinic acid), 1,5-dicafeoylqui And one or more compounds selected from the group consisting of 1,5-dicafeoylquinic acid and amentoflavon, derivatives thereof or pharmaceutically acceptable salts thereof.
  • the composition modulates the expression of an ABH antigen.
  • the material to be degraded may comprise from 0.001 weight 3 ⁇ 4 to 20 weight percent relative to the total weight of the composition.
  • the present invention is not only suitable for exhibiting the intended moisturizing effect, but also satisfies both the stability and safety of the composition, and the aspect of cost-effectiveness.
  • the composition of the present invention is a substance that controls the expression of the ABH antigen , 0.005% by weight to 19.5% by weight, 0.01% by weight to 19% by weight, 0.015% by weight to 18.5% by weight, 0.02 to the total weight of the composition Weight% to 18 weight%, 0.025 weight% to 17.5 weight%, 0.03 weight% to 17 weight 3 ⁇ 4, 0.035 weight% to 16.5 weight%, 0.04 weight% to 16 weight% or 0.045 weight% to 15.5 weight 3 ⁇ 4 Can be.
  • the composition may be a cosmetic composition.
  • the cosmetic composition is not particularly limited in formulation, and may be appropriately selected according to the purpose.
  • supple cream skin lotion and milk lotion
  • nourishing cream essence
  • nourishing cream massage cream pack
  • gel essence
  • eye cream eye essence
  • cleansing cream cleansing foam
  • cleansing water cleansing water
  • pack powder
  • the cosmetic composition may include using the formulation of the external preparation for skin in the form of an ointment, a patch.
  • Cosmetic compositions according to the invention may be provided in all formulations suitable for topical application.
  • it can be provided in the form of a formulation of emulsion, suspension, solid, gel, powder, paste, foam or aerosol composition obtained by dispersing the oil phase in a solution, aqueous phase. have.
  • Compositions of such formulations may be prepared according to conventional methods in the art.
  • the cosmetic composition according to the present invention may include other ingredients in addition to the above-mentioned substances within the range of not impairing the main effect, preferably synergistic effects on the main effect.
  • the cosmetic composition according to the present invention is a moisturizing agent, emollient, purple.
  • the sun absorber, preservatives, fungicides, antioxidants, pH adjusting agents, organic and inorganic pigments, fragrances, coolants or limiting agents may be further included.
  • the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount is 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition Can be.
  • the composition may be a pharmaceutical composition.
  • the formulation of the pharmaceutical composition according to the present invention may be a solution, a suspension, an emulsion, a gel, a drop, a suppository, a patch or a spray, but is not limited thereto.
  • the formulations can be easily prepared according to conventional methods in the art, and include excipients, wetting agents, emulsifying accelerators, suspending agents, salts or buffers for controlling osmotic pressure, colorants, spices, stabilizing agents, preservatives, preservatives. Or other commercially available adjuvants may be used as appropriate.
  • the active ingredient of the pharmaceutical composition of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Determination of dosage based on these factors is within the level of one skilled in the art, and its daily dosage is, for example, 0.000025 mg / g / day to 0.025 mg / g / day, more specifically 0.00025 mg / g / day to 0.01 m g / g / day, but is not limited thereto.
  • the pharmaceutical composition of the present invention may be administered orally or transdermally, but is not limited thereto.
  • the present invention relates to an anti-aging method of administering to a subject an effective amount of a substance that regulates the expression of A ⁇ antigen. Applying the method to a subject can inhibit or delay aging of the subject's skin.
  • the agent for controlling the expression of the ABH antigen may include a substance for increasing the expression of the ABH antigen.
  • a substance for regulating the expression of the ABH antigen 1,3-dicafeoylquinic acid (1,3-dicafeoylquinic acid), 1,5-dicafeoylquinic acid and amentoflavone
  • 1,3-dicafeoylquinic acid 1,3-dicafeoylquinic acid
  • 1,5-dicafeoylquinic acid and amentoflavone It may include, but is not limited to, one or more compounds selected from the group consisting of (amentoflavon), derivatives thereof or pharmaceutically acceptable salts thereof.
  • the agent for controlling the expression of the ABH antigen may be administered to the subject in the form of a composition, wherein the composition is a substance for controlling the expression of the ABH antigen It may comprise from 0.001% by weight to 20% by weight relative to the total weight of the composition.
  • the composition administered in the anti-aging method of one aspect of the present invention is a substance that controls the expression of the ABH antigen is 0.005% by weight to 19.5% by weight, 0.01% by weight to 19% by weight relative to the total weight of the composition, 0.015 wt% to 18.5 wt%, 0.02 wt% 3 ⁇ 4 to 18 wt%, 0.025 wt% to 17.5 wt%, 0.03 wt% to 17 wt%, 0.035 wt% to 16.5 wt%, 0.04 wt% to 16 wt%, or 0.045 It may be included in the weight% to 15.5% by weight.
  • the substance regulating the expression of the ABH antigen can inhibit the expression of matrix metal loproteinase (MMP1).
  • MMP1 matrix metal loproteinase
  • the present invention relates to a method of moisturizing skin, comprising administering to a subject an effective amount of a substance that modulates the expression of an ABH antigen.
  • the agent for controlling the expression of the ABH antigen may be a substance for increasing the expression of the ABH antigen, and specifically, 1,3-dicafeoylquinic acid ( 1,3-dicaffeoylquinic acid), 1,5-dicafeoylquinic acid (1,5 ⁇ dicafeoylquinic acid) and one or more compounds selected from the group consisting of amentoflavon, derivatives thereof or pharmaceutically acceptable Its salts may be included.
  • a substance that controls the expression of the ABH antigen may be administered to a subject in the form of a composition, and the composition may include a substance that modulates the expression of the ABH antigen. It may comprise from 0.001% to 20% by weight relative to the total weight.
  • a substance that modulates the expression of the ABH antigen is used in the above range, it is not only suitable to exhibit the moisturizing effect intended by the present invention, but also the composition of the composition. Both qualitative and safety can be satisfied and it is useful in terms of cost effectiveness.
  • the composition of the present invention comprises 0.005% by weight to 19.5% by weight, 0.01% by weight to 19% by weight, 0.015% by weight to 18.5% by weight, based on the total weight of the composition 0.02 wt% to 18 wt%, 0.025 wt% to 17.5 wt%, 0.03 wt% to 17 wt%, 0.035 wt% to 16.5 wt%, 0.04 wt% to 16 wt% or 0.045 wt% to 15.5 wt% Can be.
  • the present invention may be a substance that controls the expression of an ABH antigen for use in anti-aging.
  • the agent for controlling the expression of the ABH antigen may include a substance for increasing the expression of the ABH antigen, specifically 1,3- dicaffeoylquinic acid (1,3- dicaffeoylquinic acid), 1,5—decaffeinated One or more compounds selected from the group consisting of oilquinic acid (1,5-dicafeoylquinic acid) and amentoflavon, derivatives thereof or pharmaceutically acceptable salts thereof, but are not limited thereto.
  • Substances that control the expression of the ABH antigen may inhibit the expression of matrix metalloproteinase (MMP1).
  • MMP1 matrix metalloproteinase
  • the present invention may be a substance that modulates the expression of an ABH antigen for use in moisturizing the skin.
  • the agent for controlling the expression of the ABH antigen may include a substance for increasing the expression of the ABH antigen, specifically 1,3- dicaf feoylquinic acid (1,3-dicaf feoylquinic acid), 1,5 ⁇ It may be, but is not limited to, one or more compounds selected from the group consisting of 1,5-dicafeoylquinic acid and amentoflavon, derivatives thereof or pharmaceutically acceptable salts thereof.
  • Substances that control the expression of the ABH antigen may inhibit the expression of matrix metalloproteinase (MMP1).
  • MMP1 matrix metalloproteinase
  • the present invention may relate to the anti-aging use of a substance that modulates the expression of an ABH antigen.
  • the agent for regulating the expression of the ABH antigen may include a substance for increasing the expression of the ABH antigen, specifically 1,3-dicafeoylquinic acid (1,3-dicaf feoylquinic acid), 1,5 one It may be, but is not limited to, one or more compounds selected from the group consisting of 1,5-dicafeoylquinic acid and amentoflavon, derivatives thereof or pharmaceutically acceptable salts thereof.
  • a substance that regulates the expression of the ABH antigen can inhibit the expression of matrix PI (matrix metalloproteinase).
  • the present invention may relate to a skin moisturizing use of a substance that modulates the expression of an ABH antigen.
  • the agent for regulating the expression of the ABH antigen may include a substance for increasing the expression of the ABH antigen, and specifically 1,3-dicafeoylquinic acid (1,3—dicaffeoylquinic acid), 1,5 dicafe One or more compounds selected from the group consisting of oilquinic acid (1,5-dicafeoylquinic acid) and amentoflavon. Water, its derivatives or pharmaceutically acceptable salts thereof, but is not limited thereto.
  • Substances that control the expression of the ABH antigen may inhibit the expression of matrix metalloproteinase (MMP1).
  • MMP1 matrix metalloproteinase
  • HaCaT cells provided by Prof. Dr. N.E. Fusenig, DKFZ Heidelberg, Germany
  • 10% FBS-DMEM in 35 mm dish and starvated with 0% FBS-DMEM for 24 hours.
  • Proteins were extracted from the cells, and the cells were lysed in the same amount, and the expression of type B antigen was examined by Western blot. Alpha-leuulin protein was used as a control.
  • FBS-DMEM Dulbecco's Modified Eagle's Media
  • DMEM Dulbecco's Modified Eagle's Media
  • PBS Pulbecco's Modified Eagle's Media
  • 1,3-dicaf feoylquinic acid, 1,5-dicafeoylquinic acid and amento were changed again with medium of 0% FBS-DMEM.
  • Each flavone (amentoflavon) was treated at a concentration of 2 ug / ml and then incubated for 48 hours (control treated with DMS0).
  • the medium was collected and loaded with the same amount of medium to confirm MMP-1 by Western blot.
  • the protein was extracted from the cells and the same amount of cell lysate was loaded to confirm the expression of alpha-tubulin by Western blot.
  • MIiP-1 Collagenase
  • test substance 0.2% of the substance that controls the expression of ABH antigen was diluted. Glycerine 5% was used as a positive control.
  • the skin moisture content at the beginning, after 2 days, after 7 days, and after 11 days of the test substance was measured according to the following method with a coronometer (Corneometer CM825 (C + KGmbH, Germany)), and the results are shown in Table 1 below. .
  • the amount of moisture present in the skin's epidermis is measured by electrical measurement, and the moisture level is measured by numerically calculating the amount of moisture.
  • ⁇ ? 6> 1. Place the probe of the Koniometer on the area of skin to be measured.
  • the electrical conductivity of the skin is quantified through the sensor and displayed on the screen.
  • the average value is obtained by repeating the measurement three times at each site.
  • the composition containing a substance that regulates the expression of the ABH antigen according to the present invention was found to have excellent skin moisturizing power by effectively preserving the moisture of the skin after application.
  • a lotion is prepared according to a conventional method using the composition shown in the table below.
  • a nutritious cream is prepared according to a conventional method with the composition shown in the table below.
  • Massage cream is prepared according to a conventional method with the composition described in the table below.
  • the pack is prepared according to a conventional method with the composition shown in the table below.
  • Ointments were prepared in a conventional manner with the compositions shown in the table below.
  • (1,5-dicafeoylquinic acid) and one or more compounds in the group consisting of amentoflavon 0.0025g, vitamin C 0.0025g, red ginseng extract 50 mg, palm oil 2 mg, palm frond 8 mg of sulfur oil, 4 mg of lead, and 6 mg of lecithin were mixed and layered by 400 mg per 1 capsule according to a conventional method to prepare a soft capsule.
  • 1,3-diaffeoylquinic acid (l, 3-dicaffeoykiuinic acid), 1,5-dicafeoylquinic acid
  • one or more compounds containing 150 mg, 150 mg of vitamin C, 100 mg of glucose, 50 mg of hepatic ginseng extract and 600 mg of starch are mixed and 30% ethanol 100 mg of the granules were formed, followed by drying at 60 ° C. to form granules, which were then laminated to the fabric.
  • the final weight of the content was 1 g.
  • the composition according to the present invention contains a substance regulating the expression of the ABH antigen as an active ingredient, and has an excellent anti-aging and moisturizing effect.
  • the composition of the present invention can also be usefully used to alleviate or improve wrinkles by inhibiting MMP-1 expression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition anti-vieillissement ou hydratante pour la peau. La composition selon la présente invention contient, en tant que principe actif, une matière pour réguler l'expression de l'antigène ABH, et par conséquent, a des effets anti-vieillissement et d'hydratation de la peau améliorés. En outre, la composition de la présente invention peut inhiber l'expression de MMP-1, et par conséquent, peut être efficacement utilisée dans la réduction des rides ou l'amélioration de leur apparence.
PCT/KR2013/001756 2012-10-05 2013-03-05 Composition comprenant une matière pour la régulation de l'expression de l'antigène abh WO2014054841A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2012-0110418 2012-10-05
KR1020120110418A KR101449129B1 (ko) 2012-10-05 2012-10-05 Ａｂｈ 항원의 발현을 조절하는 물질을 포함하는 조성물

Publications (1)

Publication Number Publication Date
WO2014054841A1 true WO2014054841A1 (fr) 2014-04-10

Family

ID=50435153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/001756 WO2014054841A1 (fr) 2012-10-05 2013-03-05 Composition comprenant une matière pour la régulation de l'expression de l'antigène abh

Country Status (2)

Country Link
KR (1) KR101449129B1 (fr)
WO (1) WO2014054841A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023001385A1 (fr) * 2021-07-23 2023-01-26 Symrise Ag Compositions d'acides dicaféoylquiniques avec du tocophérol

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170239159A1 (en) * 2014-10-15 2017-08-24 Amorepacific Corporation Composition containing material for regulating expression of abh antigens
KR102199884B1 (ko) * 2014-10-15 2021-01-08 (주)아모레퍼시픽 Abh 항원의 발현을 조절하는 물질을 포함하는 피지 조절용 조성물
KR102224110B1 (ko) * 2014-10-15 2021-03-09 (주)아모레퍼시픽 Abh 항원의 발현을 조절하는 물질을 포함하는 모공 축소용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100012892A (ko) * 2010-01-21 2010-02-08 (주)아모레퍼시픽 피부 노화 진단 키트 및 피부 노화 진단 방법
KR20100082709A (ko) * 2009-01-09 2010-07-19 서울대학교산학협력단 Ａｂｈ 항원을 이용한 염증질환 개선용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100665313B1 (ko) * 2003-06-26 2007-01-09 한국과학기술연구원 항산화 및 항바이러스 활성을 가지는 화합물 및 이를포함하는 감국 추출물
KR20120009953A (ko) * 2010-07-23 2012-02-02 (주)아모레퍼시픽 아멘토플라본을 함유하는 자외선에 의한 피부 세포 손상 방지용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100082709A (ko) * 2009-01-09 2010-07-19 서울대학교산학협력단 Ａｂｈ 항원을 이용한 염증질환 개선용 조성물
KR20100012892A (ko) * 2010-01-21 2010-02-08 (주)아모레퍼시픽 피부 노화 진단 키트 및 피부 노화 진단 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DABELSTEEN, E.: "ABO blood group antigens in oral mucosa. What is new?", JOURNAL OF ORAL PATHOLOGY & MEDICINE, vol. 31, 2002, pages 65 - 70 *
DANINO, O. ET AL.: "Antioxidant activity of 1,3-dicaffeoylquinic acid isolated from Inula viscosa", FOOD RESEARCH INTERNATIONAL, vol. 42, 2009, pages 1273 - 1280 *
LEE, CHAN-WOO ET AL.: "Biflavonoids isolated from Selaginella tamariscina regulate the expression of matrix metalloproteinase in human skin fibroblasts", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 16, 2008, pages 732 - 738 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023001385A1 (fr) * 2021-07-23 2023-01-26 Symrise Ag Compositions d'acides dicaféoylquiniques avec du tocophérol

Also Published As

Publication number Publication date
KR20140044454A (ko) 2014-04-15
KR101449129B1 (ko) 2014-10-08

Similar Documents

Publication Publication Date Title
JP2018109054A (ja) 真菌感染症の治療用の局所用オイル組成物
KR20150025286A (ko) 피토스핑고신-1-포스페이트 또는 그 유도체를 포함하는 아토피 또는 피부상처 치료 또는 예방용 조성물
WO2014054841A1 (fr) Composition comprenant une matière pour la régulation de l'expression de l'antigène abh
KR20210107560A (ko) 콜히친을 포함하는 알레르기성 피부 질환 또는 피부 소양증 치료용 조성물
US10500187B2 (en) Composition comprising plant phenols for preventing or reducing TEWL and associated disorders and diseases
US20190142721A1 (en) Composition containing substance for regulating expresson of abh antigens
KR101965590B1 (ko) Ａｂｈ 항원의 발현을 조절하는 물질을 포함하는 피부 미백용 조성물
US20070275093A1 (en) Methods for Treating Non-Microbial Inflammatory Skin Conditioners
KR102199884B1 (ko) Abh 항원의 발현을 조절하는 물질을 포함하는 피지 조절용 조성물
KR20160113474A (ko) 피부 가려움증의 억제, 개선 또는 완화용 조성물
KR101548254B1 (ko) 유황, 명반 및 식초를 유효성분으로 포함하는 피부 질환 치료용 조성물
US20240225973A1 (en) Cosmetic composition for improving sensitive skin
KR20130077953A (ko) 카르노스산 또는 그 유도체를 함유하는 엘라스테이즈 활성 저해제
KR101567735B1 (ko) 면역 조절제 및 글루코사민을 포함하는 건선 예방, 개선 또는 치료용 조성물
KR101438376B1 (ko) ｐＨ 조절을 통해 안정화된 프룩토오스 1,6-디포스페이트 화합물을 함유하는 피부 외용제 조성물
KR20160066733A (ko) (2S)-1-O-리놀레노일-3-O-β-D-갈락토피라노실-sn-글리세롤을 함유하는 보습용 조성물
KR102224110B1 (ko) Abh 항원의 발현을 조절하는 물질을 포함하는 모공 축소용 조성물
KR20160067428A (ko) (2S)-1-O-리놀레노일-2-O-리놀레노일-3-O-β-D-갈락토피라노실-sn-글리세롤을 함유하는 보습용 조성물
KR20130052243A (ko) 카르노스산 또는 그 유도체를 포함하는 피부 자극 완화제
US20190175601A1 (en) Composition for inhibiting or alleviating itching including riboflavin
KR102215170B1 (ko) 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 함유하는 보습용 조성물
KR102286681B1 (ko) 진세노인 a를 함유하는 보습용 조성물
KR20160064499A (ko) 아카리시드 b6을 함유하는 보습용 조성물
KR20160066736A (ko) (2S)-1-O-리놀레오일-3-O-β-D-갈락토피라노실-sn-글리세롤을 함유하는 보습용 조성물
KR20160068193A (ko) (-)-유데스민을 함유하는 보습용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13844220

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04/08/2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13844220

Country of ref document: EP

Kind code of ref document: A1